 Company plans to initiate a Phase 12 trial of SIG-005 in patients with mucopolysaccharidosis type I MPS-1 in the second half of 2021 Company plans to initiate a Phase 12 trial of SIG-005 in patients with mucopolysaccharidosis type I MPS-1 in the second half of 2021 